In Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) for treatment of Parkinson's Disease (PD), there is a paradigm shift away from focal stimulation of target structures toward effects of stimulation on distributed brain networks. While the relationship between modulated networks and motor outcomes has received much attention, network impact of non-motor DBS effects has been less well characterized. In the affective domain, STN-DBS improves depressive symptoms in some patients, while it leads to no change or even symptomworsening in others. Here, we systematically investigate the impact of electrode placement and associated structural connectivity on changes in depressive symptoms following STN-DBS.
Introduction
For a long time, it was assumed that deep brain stimulation (DBS) exerts its function via local modulation of target structures such as the subthalamic nucleus (STN), providing relief of motor symptoms in movement disorders such as Parkinson's disease (PD) . Today, we experience a paradigm shift away from focal stimulation toward studying effects of DBS on distributed brain networks (Accolla et al., 2016; Lozano & Lipsman, 2013) . For example, a strong and robust relationship between connectivity profiles of DBS electrodes and clinical improvement has been shown in PD (Horn et al., 2017a) and recently in patients with obsessive compulsive disorder (Baldermann et al., 2019) . A currently accepted theoretical framework postulates that DBS stimulation of basal ganglia targets may lead to changes in non-motor symptoms by modulating overlapping cortex-basal ganglia motor and non-motor loops (Haynes & Haber, 2013; Krack et al., 2010) . In PD, variable effects of DBS on non-motor traits have been described in various domains including autonomic function, sleep, cognition and mood (Chaudhuri & Schapira, 2009; Dafsari et al., 2018a; 2019; Fasano et al., 2012; Kurtis et al., 2017; Witt et al., 2008; . In the affective domain, in addition to postoperative hypomania (Volkmann et al., 2010) , acute depression can also be a side effect of STN-DBS in PD patients (Funkiewiez et al., 2006 (Funkiewiez et al., , 2003 Voon et al., 2008) with a prevalence of about 20-25% (Witt et al., 2012) despite slight improvement after 6 months (Weaver et al., 2009; Witt et al., 2008) .
Interestingly, STN-DBS has been reported to improve (Campbell et al., 2012; Daniele et al., 2003) , worsen (Follett et al., 2010; Temel et al., 2006) or to have no effect (Deuschl et al., 2006; Weaver et al., 2009 ) on symptoms of depression or anxiety. However, unlike mania, postoperative depressive symptoms have rarely been associated with sensorimotor STN stimulation itself but rather with too fast tapering of dopaminergic medication (Thobois et al., 2010) and stimulation of more ventral STN territory or even zona incerta stimulation (Bejjani et al., 1999; Okun et al., 2009; Witt et al., 2012) . Indeed, the precise local placement of DBS electrodes has an effect on non-motor DBS effects (Dafsari et al., 2018b; Irmen et al., 2019; Mallet et al., 2007; Mosley et al., 2018; Witt et al., 2013) and modulation of distant brain regions involved in affective processing might play a crucial role on how affective symptoms develop after surgery.
In this study, we investigate the impact of electrode placement and associated structural connectivity on changes in depressive symptoms following STN-DBS. To this end, we reconstructed electrode placement in 80 PD patients from two international DBS centres and estimated their structural connectivity profiles. Based on these connectivity profiles, we calculated models that could explain and cross-predict worsening or improvement in depressive symptoms as measured with the Beck Depression Inventory-2 nd Edition (BDI-II; Beck et al., 1996) . Finally, we validated these models using a testing set of 36 PD patients form a third DBS centre.
Materials and methods

Patient cohorts and imaging
A total of 121 patients from three DBS centers (Berlin [BER]: n = 32; Queensland [QU]: n = 49; Cologne [CGN]: n = 40) were included in this retrospective study (age 62 ± 0.84 years, 43 women). Data from Charité Universitätsmedizin Berlin and University of Queensland were used to form the training and cross-validation datasets to identify structural connectivity predicting mood changes after DBS surgery. Data from the University Hospital Cologne was used as a test dataset to validate the established model. Five patients were excluded from the analyses for the following reasons: One patient (QU) due to incomplete data, two patients (CGN) due to unilateral VIM (instead of STN) stimulation, and two patients (CGN) due to clinically relevant psychiatric symptoms before surgery that were pharmacologically treated.
The sample characteristics of the final cohort (n = 116) are presented in Table 1 , 2007) were excluded prior to DBS by psychiatric evaluation and neuropsychological testing. Lead placement was validated using microelectrode postoperatively ON DBS in all patients and included in the analysis as covariates. Clinical data were compared pre-and postoperatively using randomized permutation tests (5000 permutations) to test for significance (p<0.05 considered significant). The study was approved by the local ethics committee at each site and carried out in accordance with the Declaration of Helsinki.
Localization of DBS electrodes
DBS electrodes were localized using the Lead-DBS toolbox (www.lead-dbs.org; Horn & Kühn, 2015) . Specifically, the advanced processing pipeline illustrated in was applied (Horn et al., 2019a) . In short, postoperative CT or MRI were linearly coregistered to preoperative MRI using advanced normalization tools (ANTs; stnava.github.io/ANTs/; Avants et al., 2008) . Coregistrations were visually inspected and refined if needed. A brainshift correction step was applied as implemented in Lead-DBS. All preoperative volumes were used to estimate a precise multispectral normalization to ICBM 2009b NLIN asymmetric ("MNI") space applying the ANTs SyN Diffeomorphic Mapping method (Avants et al., 2008) using the preset "effective: low variance default + subcortical refinement" implemented in Lead-DBS. In some patients where this strategy failed, a multispectral implementation of the Unified Segmentation approach (Ashburner & Friston, 2005) implemented in Statistical Parametric Mapping software (SPM12; http://www.fil.ion.ucl.ac.uk/spm) was applied. These two methods are available as presets in Lead-DBS and were top-performers to segment the STN with precision comparable to manual expert segmentations in a recent comparative study (Ewert et al., 2019) . DBS contacts were automatically pre-reconstructed using PaCER (Husch et al., resulting gradient vector magnitude was thresholded at a heuristic value of 0.2 V/mm to generate the VTA.
Recently, it has been shown that using binarized VTAs (that would model all-or-nothing activations) could predict slightly less variance in clinical outcomes in comparison to using weighted VTAs such as the E-field gradient vector magnitudes . Binary VTAs are based on specific thresholds that assume a certain type of axon diameter and orientation and do not grasp the anatomical complexity of the subcortex (e.g. Forstmann et al., 2016) . To account for this general limitation of the VTA concept, we repeated all analyses using the unthresholded E-field magnitude instead of the VTAs surrounding the active electrode contacts for the connectivity analysis (see for details).
Whole-brain structural connectivity profiles seeding from bilateral VTAs or E-Fields were estimated using a Parkinson's Disease group connectome that is based on publicly available PPMI normative connectome of PD patients (age n = 90; age 61.38 ± 10.42, 28 female) was priorly computed (Ewert et al., 2017) and has been used in context of DBS multiple times before (Horn et al., 2017a (Horn et al., , 2017b Neumann et al., 2018) . For each patient, fibers that passed through the VTA or a non-zero voxel of the E-Field were selected from this normative connectome and projected onto a voxelized volume in standard space (1mm isotropic resolution) while keeping count of the fibers traversing each voxel. In the binary (VTA) analyses, the number of fibres traversing each voxel were denoted (resulting in classical fibredensity map), in the E-Field based analyses, each fibre received the weight of the maximal E-Field magnitude of its passage and fibre densities were weighted by these values. Figure 1 provides an overview over the methodology applied. that traversed through each patient's VTA were selected and projected to the brain as fiber density maps. These maps represent the structural connectivity "fingerprint" seeding from each VTA. B) Varying electrode placement leads to different connectivity "fingerprints" in each patient. Across the group of patients, these fingerprints are used to generate a model of connectivity that is associated with maximal BDI-II improvement by voxel-wise correlation ("R-Map"). C) The R-Map represents a model that denotes how electrodes should be connected to result in maximal BDI-II improvement. When comparing each novel patient's "fingerprint" with this model (by means of spatial correlation), individual BDI-II improvement can be predicted. Crucially, this is done to predict improvement in out-of-sample data, i.e. across cohorts or in a leave-one-out fashion throughout the manuscript. This means that the R-map is never informed by the predicted patient's structural connectivity "fingerprint".
Validation of the training dataset. One R-map for each subset (BER, QU) was calculated. Rmaps were then used to predict BDI-II changes in out-of-sample data (i.e. cross-predicting between QU ⬌ BER cohorts) by spatial correlation between the R-map (model) and the connectivity profile seeding from the VTAs in each patient. This was done across voxels with an absolute Spearman's R-value of > 0.1 on each R-map. For example, the R-map (model) was calculated across the BER sample and voxels with an absolute R > 0.1 were spatially correlated with connectivity maps in the QU sample. For each patient in the QU cohort, this led to one Rvalue that coded for spatial similarity to the model. These R-values were then correlated with empirical BDI-II changes. An additional leave-one-out cross-validation (i.e. data from patients 1-79 was used to predict patient 80 and so on) across the training sample (BER/QU combined) was run to test whether similarity to the specific structural connectivity profile of the training set (which is denoted by the R-map) could significantly predict absolute BDI-II change.
Furthermore, we validated the results by running the analyses again based on the E-field instead of VTA; using the percentage BDI-II change relative to baseline instead of the absolute BDi change. Moreover, to test for potential lateralization of connectivity profile, we reran analyses for left and right VTAs separately.
Prediction of the test dataset. In the same fashion as the cross-prediction between the subcohort of the training dataset, a joint R-map for the entire training/cross-validation set (BER+QU) was generated, which was used to predict data BDI-II change in patients of the test dataset (CGN).
Testing robustness of the model across the entire sample. We applied the leave-one-out crossvalidation across the whole dataset, i.e. data from patients 1-115 was used to predict patient 116 and so on. Finally, to control for the effect of postoperative LEDD and UPDRS-III reduction, those variables were included in the prediction models as covariates.
Isolation of fibertracts that are discriminative for mood changes
In an additional analysis, we sought to identify tracts that could discriminate patients with positive from negative BDI-II change. For each fibertract in the normative connectome (PPMI 90, see above), its accumulative E-Field vector magnitude while passing by each patient's electrode was denoted. This value was then Spearman rank-correlated with each patient's clinical change in depressive symptoms. Thus, a fibertract that passed close to active contacts of patients that had BDI-II improvement but far from active contacts in patients that had BDI-II worsening would receive a high Spearman's R value (and tracts exhibiting the inverse property received a highly negative R value). These R values were used to color-code fibertracts that were positively and negatively predictive of BDI-II improvement. This analysis was expected to show identical (or highly similar results) as the "R-map" method explained above but with the advantage of working on a tract-by-tract basis (instead of a voxel-wise fashion).
Thus, it is ideal to visualize the actual fibertracts that were predictive of change in depressive symptoms. Given the similarity of the methodology, this analysis was only performed once on the complete set of patients to further characterize the tracts that are likely responsible for BDI-II changes under STN-DBS. The fibertract analysis was validated across the whole data set with a leave-one-cohort-out cross-prediction, which predicted data of any one of the three DBS centres by data of the two other centers following the procedure of Li et al., 2019 .
Results
Clinical data
Disease duration in the entire sample (n = 116; Table 1 ; Supplementary Table 1 for more details) was 9.55 ±4.45 years. DBS lead placement was similar across all three cohorts (Figure 2A,3C ).
Motor improvement with DBS was significant although we measured it ON medication reaching an average DBS response of 27.56 ±8.37 % (i.e. M ±SEM throughout the paper) as measured by the UPDRS-III. Preoperative LEDD was 1142.46mg ±52.69 as compared to postoperative 464.45mg ±27.05 (56.55 ±2.77 % reduction) with a contribution of dopamine agonists (DA) of 191.06mg ±16.62 pre-and 107.51mg ±10.73 postoperatively. Total LEDD, LEDD of DA, and UPDRS-III reduction were not significantly different in training and test datasets (p > 0.05 for all three variables, see table 1 for mean values). On average, BDI-II scores decreased from 9.94 ±0.50 to 8.96 ±0.60 (on average by 0.97 ±0.54 points = absolute BDI-II change) postoperatively, i.e. there was an overall reduction in BDI-II of 3.34 ± 8.12% but the difference was not significant. Importantly, scores in some patients improved while others worsened (with an absolute BDI-II change in single patients -of up to 19, Supplement 1). In the test dataset ( Supplementary Table 1 -Cologne), some specific features were noted: patient #10 and #19 were diagnosed with comorbid depression and anxiety disorder at baseline; patient #13 reported pain and relatedly negative mood. Those three patients are marked with asterisk in Figure 3B . 
Connectivity related to DBS-induced mood changes
We identified a VTA-based structural connectivity map (R-map) predictive of postoperative BDI-II change in the training dataset ( Figure 3A ). The more fibers connected a patient's VTA to the positive areas (warm colors) of this map, the more their depressive symptoms improved postoperatively. On the contrary, the more a patient's VTA was structurally connected to the negative areas (cold colors) of this map, the more their depressive symptoms worsened postoperatively.
Validation of the training dataset. The R-maps of the two subcohorts in the training dataset were similar: On the right hemisphere of the R-map, connectivity to motor and prefrontal regions is universally associated with depressive symptom improvement. On the left hemisphere however, connectivity to the prefrontal cortex (PFC), including the dorsolateral PFC is strongly associated with worsening of depressive symptoms, whereas connectivity to sensorimotor and superior parietal areas is associated with symptom improvement (Figure 2 ).
Cross-predictions were significant, i.e. the R-map based on BER-data could predict BDI-II change in relation to structural connectivity in the QU dataset ( Figure 2C , R = 0.52, p < 0.0001) and vice versa (R = 0.57, p < 0.0001). In a leave-one-out cross-validation across the training sample (BER/QU combined), similarity to this specific structural connectivity profile (which is denoted by the R-map) could significantly predict absolute BDI-II change (R = 0.26, p = 0.01) even when basing structural connectivity profiles on the E-field instead of VTA (R = 0.24, p = 0.015) or when using the percentage BDI-II change relative to baseline (R = 0.20, p = 0.04). To test whether the effect was lateralized to either hemisphere, we reran analyses for left and right
VTAs separately and found that connectivity on either hemisphere alone was predictive for BDI-II change as well (right: R = 0.347, p = 0.002; left: R = 0.359, p = 0.001).
Prediction of the test dataset. The R-map based on the whole training set (BER/QU combined) was used to predict BDI-II change in the independent test dataset (CGN) by calculating spatial similarity between each CGN-patient's electrode connectivity profile with the BER/QU R-map.
This could again validate our results and a significant correlation was observed ( Figure 3B , R = 0.36, p = 0.012).
Testing robustness of the model across the entire sample. Although the CGN cohort was kept isolated from data-analysis until this very last step, we opted to create one final R-map across all available data to calculate a final connectivity profile that codes for BDI-II change based on all information present. This final connectivity map predictive for BDI-II change in all three cohorts (n = 116) is displayed in Figure 4A . To further validate robustness of this final R-map, we performed one last leave-one-out cross validation analysis ( Figure 4B , R = 0.33, p < 0.001).
Moreover, this prediction model remained significant when including postoperative LEDD reduction, reduction of dopamine agonists and percentage UPDRS-III change (postoperativepreoperative) as additional covariates and correcting for cohort in a joint general linear model (R 2 = 0.21, F(112,105) = 4.78, p = 0.0002). Thus, this final model was able to explain 21% of variance in BDI-II change based on clinical covariates and structural connectivity profiles across the whole group of subjects.
Fibertracts related to mood changes
An additional analysis was run to identify the actual tracts (instead of their cortical projection sites) that were correlated with BDI-II improvement when modulated. This was done on a tractby-tract instead of voxel-wise basis but further confirmed our results using a different analysis pathway. Crucially, this data-driven analysis revealed largely more tracts on the left hemisphere than on the right hemisphere, again suggesting an impact of left DBS stimulation on change of depressive symptoms ( Figure 5A ). Using lower thresholds, the pattern was similar between the two hemispheres but left hemispheric tracts were more predictive of BDI-II change and predictive tracts were found in larger quantities. The analysis revealed that the positively and negatively associated tracts seemed to differ in their anatomical course in that the negatively associated tract passed by the STN medial and at level of its limbic/associative functional zone, while the positively correlated tract passed through and slightly lateral to the motor STN ( Figure   5B ). Moreover, as can be seen in Figure 5C , the negatively associated tract traverses more laterally when ascending to the PFC. Robustness of this tract was validated using leave-onecohort-out crossvalidations which supported the results from our R-map model: any of the cohorts could be predicted by the other two cohorts (BER/QU predicting CGN; QU/CGN predicting BER; BER/CGN predicting QU) R = 0.24, p = 0.001. At this threshold level, no fibers on the right hemisphere were associated with clinical improvement but a strong set of both positive and negative fibers were found on the left hemisphere. B) View from the left and C) view parallel to the longitudinal axis of the left STN. Positively and negatively correlated fibertracts seem to be distinct tracts, the positive one passing through the STN and lateral to it, the negative one medial and anteriorly. D) Superimposed on a section of the BigBrain ultrahigh resolution human brain model (Amunts et al., 2013) , at the level of the brainstem, the negative tract seems to traverse around the red nucleus and may connect to (or originate from) brainstem nuclei such as the left dorsal raphe nucleus (shown in dark blue as defined by the Harvard Ascending Arousal Network Atlas; (Edlow et al., 2012) ).
Discussion
In this study, we modelled structural connectivity predictive for changes in depressive symptoms following STN-DBS. We identified a robust connectivity pattern linking worsening of depressive symptoms to left prefrontal impact. Three main conclusions can be drawn from these results. First, a distinct VTA-based structural connectivity profile can predict long-term change in depressive symptoms associated with STN-DBS in PD patients. Second, the connectivity profile is robust and able to predict data across cohorts and in an independent test sample. Third, left-hemispheric negative connectivity to the PFC predicting less benefit of DBS on depressive symptoms in our cohort may suggest that anteromedial fibers to left prefrontal areas should be avoided for left STN-DBS lead placement to maximise improvement of depressive symptoms.
A common assumption in clinical research on affective changes associated with STN-DBS is that they result from rapid withdrawal of dopaminergic replacement therapy after surgery (Thobois et al., 2010) increasing anhedonia induced through dysregulation in affective networks (Belujon & Grace, 2017; Dunlop & Nemeroff, 2007) . While this is an important factor explaining acute and subacute postoperative affective changes, in our large multi-center sample using long-term data, LEDD reduction did not explain BDI-II change. Perhaps this relates to clinicians addressing this potential risk-factor for depression during long-term follow up.
Others have also reported a lack of correlation between LEDD reduction and non-motor PD symptoms like apathy and mood (Dafsari et al., 2018; Dafsari et al., 2018b ). Yet, the general notion is that STN-DBS mimics the action of dopaminergic agents (Volkmann et al., 2010) and
acute stimulation more likely leads to hypomania as depression (Appleby et al., 2007; Castrioto et al., 2014; Funkiewiez et al., 2003; Krack et al., 2010; Romito et al., 2002; Volkmann et al., 2010; Witt et al., 2008) potentially relating to stimulation of contacts in the anterior, ventral and medial planes (Chopra et al., 2011) . Interestingly, long-term improvement in motor symptoms as measured with UPDRS-III did not add to the explanation of BDI-II change by connectivity in our sample, suggesting that stimulation may influence affective processing more directly, i.e. via connectivity to limbic/prefrontal areas.
The association of depressive symptoms and connectivity to the left PFC is not surprising given the vast amount of evidence linking depression to left frontal lesions. Specifically, hypoactivity and dysfunction of the left PFC is commonly found in patients with depression (Chang et al., 2011; Grimm et al., 2007; Hamilton et al., 2012; Koenigs et al., 2008; Mayberg et al., 2005; Thomas et al., 2003) and there is an increase of depressive symptoms after left dlPFC traumatic brain injury (Fedorof et al., 1992; Jorge et al., 2004; Leung et al., 2018) and stroke (Egorova et al., 2017; Grajny et al., 2016; Hama et al., 2007; Shi et al., 2017) . In particular, Grainy et al.
(2016) found that severity of depression is directly related to the extent of dlPFC damage suggesting gradual impact of frontal damage on networks underlying depressive symptoms.
Indeed, large-scale network effects, hemispheric asymmetries and connectivity play an important role in the development of depressive symptoms; e.g. post-stroke depression has been linked to altered functional connectivity of dlPFC to the frontoparietal cognitive control network (Egorova et al., 2017) and dlPFC connectivity in general plays a major role in depression (Hwang et al., 2015; Kaiser et al., 2015; Sheline et al., 2010) . In particular, the left dlPFC seems to be regulating negative affect through reappraisal and voluntary suppression (Koenigs et al., 2010; Lévesque et al., 2003; Ochsner et al., 2004; Phan et al., 2005) via the frontoparietal cognitive control network (Pan et al., 2018) . In patients suffering from major depression, excitability of the hypoactive dlPFC tissue (Chang et al., 2011; Grimm et al., 2007; Hamilton et al., 2012; Koenigs et al., 2008; Mayberg et al., 2005; Thomas et al., 2003) has been augmented with non-invasive brain stimulation using high-frequency repetitive transcranial magnet stimulation (rTMS) leading to symptom amelioration (Pascual-Leone et al., 1996) . Although the precise mechanism of dlPFC rTMS in improving depressive symptoms
is not yet fully understood, a role of local and remote network changes and altered connectivity of prefrontal structures is evident (Fox et al., 2012 (Fox et al., , 2013 Philip et al., 2018) . Interestingly, the common targets of rTMS in depression that have been summarized by Fox et al. (2013) precisely lie within the clusters we find negatively associated with BDI-II improvement under STN-DBS; Figure 4C ). Thus, when depressive symptoms worsen under long-term STN-DBS, the VTAs are tempering fibers linked to the left dlPFC.
When asking why structural connectivity from VTAs to the left dlPFC explains depressive symptom change, several aspects should be considered. First, a correlation of fibertracts with BDI-II change clearly shows that worsening of depressive symptoms under STN-DBS is associated with fibers connecting prefrontal areas via zona incerta to the dorsal mesencephalon and brainstem ( Figure 5 ). We presume that STN-DBS may disrupt information flow along these connecting fibers between prefrontal areas and the brainstem. One candidate brainstem region whose link to the PFC might be disturbed by DBS leading to depression is the dorsal raphe nucleus (DRN), which is part of the serotonergic system that is known to impact mood states (Michelsen et al. , 2008; Politis et al., 2010; Wei et al., 2018) and which is hypoactive in depression (Michelsen et al., 2007) . Indeed, unbalanced connectivity of the DRN and prefrontal areas is related to depression (Ikuta et al., 2017) and abnormal serotonergic neurotransmission has been -albeit inconsistently -linked with depression in PD (Politis et al., 2010; Qamhawi et al., 2015) . Moreover, rodent studies have shown that STN-DBS may inhibit serotonergic output from the DRN (Hartung et al., 2011) and that this induces depressive-like behavior Temel et al., 2007) . Since there are no direct connections between the STN and the DRN (Peyron et al., 1997) , one of the candidate neural pathways underlying the serotonergic suppression effect of STN-DBS is prefrontal-DRN connectivity . Indeed, excitatory input from (medial) prefrontal areas directly modulates activity of serotonergic neurons in the DRN (Hajós et al., 1998; Varga et al., 2001; which as the origin of the meso-cortico-limbic dopamine projections is pivotal for rewardprocessing but also plays a role in depression (Wei et al., 2018; Wohlschläger et al., 2018) . Yet, this neural substrate is less likely given the exact anatomical course of the tract.
Second, it is worth mentioning that like the striatum, the STN is a node of convergence of affective, cognitive and motor input (Accolla et al., 2016; Alexander & Crutcher, 1990; Aron et al., 2016; Haynes & Haber, 2013; Péron et al., 2013; Sieger et al., 2015) . Its activity is modulated through coupling with PFC activity (Cavanagh et al., 2011; Frank et al., 2007; Herz, Zavala, Bogacz, & Brown, 2016) and, crucially, STN-DBS impacts affective processing (e.g. Irmen et al., 2017; Péron et al., 2010) . Therefore, although here we see activation of fibertracts associated with BDI-II change passing medially by the STN, a role of the structure in affective processing and emotion regulation is undisputed (Campbell et al., 2008; Mallet et al., 2007; Péron et al., 2015) . Importantly, in our data, depressive symptoms improved if predominantly fibers connecting the dorsolateral (motor) STN to the motor cortex were stimulated as has been reported before (Eisenstein et al., 2014) . This implicates the overlapping presence of neurons involved in affective/associative processing and motor processing in the STN motor segment (Accolla et al., 2017; Haynes & Haber, 2013; Irmen et al., 2019) . In turn, as a secondary effect, STN-DBS may impact subcortical-cortical structural connections by changing integration of balanced input from cognitive, affective and motor loops in the basal ganglia and related networks (Accolla et al., 2014 (Accolla et al., , 2016 Haynes & Haber, 2013; Irmen et al., 2019; Rodriguez-Oroz et al., 2011) . The left-hemispheric laterality of the observed effect might however be specific to depression since other studies stressed the role of the right STN in the processing of positive emotional voices (Eitan et al., 2013) and stimulation of the right STN is associated with neuropsychiatric symptoms such as disinhibition (Mosley et al., 2018) . These results are not mutually exclusive with our findings since they differ in their approach (network vs. local target anatomy and physiology). Effects of STN-DBS on cognition and affect are complex and we are only starting to understand the associated local, network, and physiological changes.
Taken together, in the left hemisphere, high-frequency stimulation of fibers anteromedial to the STN is associated with worsening of depressive symptoms while stimulation of dorsolateral STN leads to improvement of depressive symptoms in PD patients. The connectivity profile described in this study may be used to inform surgeons and clinicians in the placement and settings of STN-DBS, depending on the patient's individual connectivity that could be studied before surgery. Certainly, more work is needed to refine our understanding of the functionality of prefrontal to STN connectivity and the left-lateralized hemispheric impact; but this study introduces a new direction of avoiding harmful side effects of STN-DBS in PD patients by considering connectivity to networks guiding these side effects.
As a final consideration, it is important to stress that we believe depression is a system-level disorder: no single brain region or neurotransmitter is the sole driving force but instead, integrated networks of cortical and subcortical regions seem to be key (Mayberg et al., 2005) .
This means the impact of STN-DBS on affective networks based on patients' connectivity profiles is surely not the only factor contributing to changes in depressive symptoms.
Importantly, our patients had minor to moderate depressive symptoms that were partially modulated by DBS but none of them had a severe depression. Yet, this research may contribute to better understand, avoid and treat affective side effects like depressive symptoms in patients with STN-DBS.
There are several limitations that should be considered when interpreting our findings. First, there might be differences in the assessment of depressive symptoms across DBS centres, that is e.g. whether patients reported their mood state at the first or the last day of their follow-up stay when clinical interventions taken might already have improved their mood state. We do believe though that with our large sample size slight variances in the timepoint of BDI-II assessment did not systematically bias our results. Secondly, there is a variation in electrode type in the patients included in this study. This could have effects on the VTA model, e.g. by the respective consideration of constant voltage versus constant current default settings in DBS systems by Medtronic vs. Boston Scientific. To circumvent a bias of this factor, we reran analyses using the unthresholded E-field that surrounded electrodes and found the similar results. Third, we used a Parkinson-specific normative connectome for our analysis purposes, which assumes structural connectivity to be approximately the same in all patients of our sample. While this assumption might not hold true in all cases, the method has been used and validated in several recent studies with DBS context (Baldermann et al., 2019; Horn et al., 2017a; Neumann et al., 2018) . Beyond practical advantages (where patient-specific connectivity data is often not available and cannot be acquired postoperatively), normative connectomes have often been acquired on specialized MRI hardware and comprise of a high N of subjects (such in this sample of patients from the PPMI project). Thus, the use of normative connectomes has the advantage of high signal-to-noise levels and state-of-the-art data quality.
Finally, we only had UPDRS-III scores ON medication (preoperative vs. ON stim) in our sample. Thus, the pre-to postoperative comparison might not reflect the full impact of STN-DBS on motor symptoms. However, since the BDI-II maps we calculated are very robustly predictive in out-of-sample data (cross-predicting between BER and QU, predicting CGN from BER/QU and predicting each patient's BDI-II improvement of the whole sample in a leaveone-out fashion), the effects of UPDRS-III improvement do not seem to have a strong impact on BDI-II either way.
In conclusion, the present results have a potential therapeutic value for the refinement of brain stimulation targets. In personalized brain stimulation, identifying proximity to fibres connecting the electrode with the left dlPFC might have a prognostic utility in predicting change in depressive symptoms under STN-DBS. Prospectively, connectivity maps as the one presented here as well as isolated fibertracts can be used in surgical planning to optimize positioning of DBS leads in PD patients. Furthermore, with the use of directional leads, the electrical field could be guided away from fibertracts anteromedial to the left STN, the stimulation of which was associated with depressive symptoms in our study. Importantly, this study specifically shows that the STN connectivity profiles might have to be treated differently for the right and left hemisphere. However, more work is needed to validate this presumption based on patientspecific connectivity. Altogether, our findings lead to a better understanding of how negative mood effects may originate following STN-DBS and pave the way toward personalized brain stimulation in which individual connectivity profiles and symptom constellations determine optimal DBS targets.
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